Shionogi & Co. | Sustainability Performance

https://www.shionogi.com/global/en/

Researches, develops, and manufactures pharmaceutical products, with activities spanning infectious diseases, central nervous system treatments, and specialty healthcare solutions.

1878

Japan

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$1B - 10B in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#4260

Overall

#192

in Japan

#96

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

105 out of 312

Overview

Environmental

Carbon emissionsEnergy consumptionWaste managementWater managementAir and land impactNature and biodiversityNature riskClimate risk

Social

Diversity and inclusionPay gapsHealth and safetyExternalities

Governance

TargetsSDG ImpactESG scores and exclusionsB-corp & CDP

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Rici Healthcare

Japan, Hospital & Health Care, Hospital & Health Care

Santen Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Takeda Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

CO2 scope 1 + 2

89.8K CO2e tonnes, 2025

Laggard

Renewable energy

19% 2025

Laggard

Waste generated

5.6K tonnes, 2025

Aligned

Female engagement

42% 2024

Laggard

Externalities

8.2M $, 2025

Leading

Market cap

383.0T $, 2026▲10.9% YoY

Revenue

3.3B $, 2026▲12.3% YoY

R&D intensity

24.58% 2026

Intensity

Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)

Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)

Energy consumption (direct) intensity (MWh /$M)

Waste generation intensity (tonnes /$M)

Industry Benchmark

26.9

B/M 13.9

80.5

B/M 114.3

99.7

B/M 35.7

1.7

B/M 0.3

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Shionogi & Co Ltd, Japanese major pharma (Crestor/rosuvastatin codeveloper, COVID19 oral antiviral Xocova/ensitrelvir), has faced multiple US class actions over the contested historic 2024 sustained scrutiny over Xocova/ensitrelvir clinical trial data and the Japanese government emergency approval pathway disputes affecting Japanese institutional shareholders amid Japanese pharma sector regulatory pressure.

Carbon emissions breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******

Energy consumption breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	-	-	*******
*******	*******	-	-	-	-	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	-	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Waste management

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	-	-	*******	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	-	-	*******	-	-	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	-	-	*******
*******	*******	-	-	-	*******	*******	*******
*******	*******	-	*******	*******	-	-	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	-	-	*******

Air pollution

Reveal data for 2 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******

KPI	Metric	Year
	2021	2022	2023	2024	2025	Benchmark
*******	*******	-	-	-	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SBTi targets and commitments

Target	Status	Temperature alignment	Year
Near-term target	Targets set	1.5°C	FY2031
Long-term target	Not disclosed	-	-
Net-zero	Not disclosed	-	-
Business Ambition 1.5°C	Not disclosed	-	-

Target details

SHIONOGI commits to reduce absolute scope 1 and 2 GHG emissions 46.2% by FY2030/31 from a FY2019/20 base year. SHIONOGI commits to reduce absolute scope 3 GHG emissions from purchased goods and services 20% by FY2030/31 from a FY2019/20 base year.

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Total sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Shionogi & Co Ltd, Japanese major pharma (Crestor/rosuvastatin codeveloper, COVID19 oral antiviral Xocova/ensitrelvir), has faced multiple US class actions over the contested historic 2024 sustained scrutiny over Xocova/ensitrelvir clinical trial data and the Japanese government emergency approval pathway disputes affecting Japanese institutional shareholders amid Japanese pharma sector regulatory pressure.

Shionogi & Co. | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Renewable electricity

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

SBTi targets and commitments

Target details

Overall score

Environment

Social

Governance

Exclusion screening

CDP Scores

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Shionogi & Co. | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Renewable electricity

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package